Acepodia Advances Modular Cell Therapy Platform with Antibody-Cell Conjugation (ACC) Technology

On September 18, Acepodia, Inc. announced that Professor Carolyn Bertozzi (winner of the 2022 Nobel Prize in Chemistry) will serve as the company's Chief Scientific Advisor to support the further development of its ACC (Antibody-Cell Conjugation) technology platform and related projects. The author conducted a brief study on the company’s core technology platform and associated projects and shares insights with readers. According to the official website, the ACC technology essentially uses bioorthogonal chemical reactions compatible with living cells (originating from Professor Bertozzi’s lab) to conjugate tumor-targeting antibodies onto the surface of immune cells, thereby enhancing the ability of immune cells to recognize cancer cells (including solid tumor cells).